Stephanie Graff: First 3rd-generation HER2-directed ADC in neoadjuvant HER2+ Breast Cancer
Stephanie Graff, Director of Breast Oncology at Brown University Health and an Associate Professor of Medicine at Brown University’s Legorreta Cancer Center, shared a post on X:
“First 3rd-generation HER2-directed ADC in neoadjuvant HER2+ BC.
SHR-A1811 monotherapy is efficacious (PCR 63.2% and well tolerated.,
Is there a future where we can build on an ADC instead of the current standard of care 4 drug combo?”
Stephanie Graff is the Director of Breast Oncology at Brown University Health and an Associate Professor of Medicine at Brown University’s Legorreta Cancer Center. She also serves as the Director of Breast Oncology at Lifespan and is a Medical Advisor for the Dr. Susan Love Foundation for Breast Cancer Research.She is an Associate Editor of Cancer Medicine, and chairs the editorial board of Oncology Times.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023